Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study
暂无分享,去创建一个
T. Rainis | A. Agbarya | L. Saiegh | M. Sheikh-Ahmad | I. Matter | J. Bejar | Hila Kreizman-Shefer | F. Swaid | Ekaterina Yovanovich | Majd F. Sirhan | Monica Laniado | Anan Shalata | Nama Mubariki | Ilana Rosenblatt
[1] N. Stephens,et al. New Developments in Gastric Neuroendocrine Neoplasms , 2022, Current Oncology Reports.
[2] E. Pilozzi,et al. Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre study. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[3] H. Köseoğlu,et al. Gastric neuroendocrine neoplasms: A review , 2021, World journal of clinical cases.
[4] D. Metz,et al. Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome , 2021, Annals of Surgical Oncology.
[5] G. Lee,et al. Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor , 2021, Journal of Gastrointestinal Surgery.
[6] C. Shi,et al. Gastric neuroendocrine tumours from long‐term proton pump inhibitor users are indolent tumours with good prognosis , 2020, Histopathology.
[7] P. Sarder,et al. Improving the accuracy of gastrointestinal neuroendocrine tumor grading with deep learning , 2020, Scientific Reports.
[8] D. Pritchard,et al. Systematic review: management of localised low‐grade upper gastrointestinal neuroendocrine tumours , 2020, Alimentary pharmacology & therapeutics.
[9] Qiyun Tang,et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research , 2020, Gastric Cancer.
[10] A. Faggiano,et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[11] G. Kaltsas,et al. Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms , 2019, Clinical endocrinology.
[12] G. Kaltsas,et al. Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis , 2019, World journal of gastroenterology.
[13] E. Pilozzi,et al. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center , 2019, Journal of clinical medicine.
[14] F. Campbell,et al. Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis , 2017, British journal of clinical pharmacology.
[15] P. Ruszniewski,et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms , 2016, Neuroendocrinology.
[16] C. Divino,et al. Management and Disease Outcome of Type I Gastric Neuroendocrine Tumors: The Mount Sinai Experience , 2015, Digestive Diseases and Sciences.
[17] W. Travis,et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] G. Kaltsas,et al. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms , 2014, Clinical endocrinology.
[19] G. Kaltsas,et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? , 2013, World journal of gastroenterology.
[20] I. Modlin,et al. Gastric carcinoids (neuroendocrine neoplasms). , 2013, Gastroenterology clinics of North America.
[21] Mohid S. Khan,et al. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms , 2013, British Journal of Cancer.
[22] G. Kaltsas,et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. , 2013, European journal of endocrinology.
[23] E. Pilozzi,et al. Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate , 2011, Neuroendocrinology.
[24] M. Coleman,et al. Carcinoid Tumors of the Gastrointestinal Tract: Trends in Incidence in England Since 1971 , 2010, The American Journal of Gastroenterology.
[25] B. Niederle,et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.
[26] S. Willich,et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. , 2008, Endocrine-related cancer.
[27] B. Skogseid,et al. Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.
[28] S. Willich,et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.
[29] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] E. Wilander,et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids , 1998, Gut.
[31] D. Ravizza,et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study , 2015, Endocrine.